ArticleJournal of clinical medicine2022
Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.Current allergy and asthma reports · 2025Pooled it
- Efficacy of Biologic Therapies for Eosinophilic Otitis Media: A Systematic Review and Meta-analysis.The journal of international advanced otology · 2024Pooled it
- Galectin-10 and Charcot-Leyden Crystals in Chronic Rhinosinusitis with Nasal Polyps: Pathogenetic Insights and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Cycling biologic therapy with tezepelumab and mepolizumab for eosinophilic otitis media and eosinophilic pneumonia in a patient with asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Effect of adding biologic agents to disease-modifying anti-rheumatic drugs for refractory chronic suppurative otitis media: comparative outcomes and cytokine-driven mechanisms.American journal of translational research · 2026Article
- Efficacy of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Eosinophilic Otitis Media: A Six-Month Observational Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Biologic Therapy Relieves Otologic Symptoms and Signs in Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps.Laryngoscope investigative otolaryngology · 2025Article
- Article
- Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases.Lung India : official organ of Indian Chest Society · 2025Article
- Biologics for eosinophilic otitis media: a retrospective case study in a multidisciplinary center.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Observational
- Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy.Frontiers in allergy · 2025Article
- Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2023Article
- QoL Following Dacryocystorhinostomy: Linguistic Adaptation of Italian Version of GBI.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023Article
- The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma.Current allergy and asthma reports · 2023Review
- Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review.Journal of personalized medicine · 2022Review
- Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A "Real-Life" Observational Study in the First Year of Treatment.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media characterized by eosinophilic accumulation in the middle ear mucosa and effusion. It is resistant to conventional treatments and strongly associated with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of our study is to evaluate the effectiveness of biologics drugs in the control of EOM. This is a retrospective no-profit real-life observational study, involving patients affected by refractory EOM and in treatment with different biologics for concomitant severe eosinophilic asthma or severe uncontrolled CRSwNP (Dupilumab:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.